Michael Heuser

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/152450/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia, 2022, 36, 90-99.	7.2	42
2	A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2. Journal of Medicinal Chemistry, 2022, 65, 1171-1205.	6.4	10
3	Reduced intensity hematopoietic stem cell transplantation forÂaccelerated-phase myelofibrosis. Blood Advances, 2022, 6, 1222-1231.	5.2	20
4	Midostaurin plus intensive chemotherapy for younger and older patients with AML and <i>FLT3</i> internal tandem duplications. Blood Advances, 2022, 6, 5345-5355.	5.2	24
5	MO343: Deep Analysis of The AKI—CKD in Allogeneic Stem Cell Transplantation—A Big Data Approach. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
6	Changes in health-related quality of life in patients with newly diagnosed acute myeloid leukemia receiving ivosidenib + azacitidine or placebo + azacitidine Journal of Clinical Oncology, 2022, 40, e19024-e19024.	1.6	0
7	Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation. Transplantation and Cellular Therapy, 2022, , .	1.2	1
8	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
9	Hematologic improvements with ivosidenib + azacitidine compared to placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia Journal of Clinical Oncology, 2022, 40, 7042-7042.	1.6	0
10	Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine Journal of Clinical Oncology, 2022, 40, 7019-7019.	1.6	0
11	Amplified <i>EPOR</i> / <i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia. Blood Cancer Discovery, 2022, 3, 410-427.	5.0	7
12	Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia. Haematologica, 2021, 106, 565-573.	3.5	29
13	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia, 2021, 35, 62-74.	7.2	63
14	Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up. Annals of Hematology, 2021, 100, 595-599.	1.8	5
15	IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis. Leukemia, 2021, 35, 1301-1316.	7.2	30
16	Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies. Journal of Clinical Pharmacology, 2021, 61, 349-359.	2.0	2
17	Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. Transplantation and Cellular Therapy, 2021, 27, 95.e1-95.e4.	1.2	12
18	Newly diagnosed isolated myeloid sarcoma–paired NGS panel analysis of extramedullary tumor and bone marrow. Annals of Hematology, 2021, 100, 499-503.	1.8	9

#	Article	IF	CITATIONS
19	Germline variants drive myelodysplastic syndrome in young adults. Leukemia, 2021, 35, 2439-2444.	7.2	43
20	Unbalanced translocation der(5;17) resulting in a TP53 loss as recurrent aberration in myelodysplastic syndrome and acute myeloid leukemia with complex karyotype. Genes Chromosomes and Cancer, 2021, 60, 452-457.	2.8	2
21	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Annals of Hematology, 2021, 100, 1181-1194.	1.8	27
22	A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. Blood Advances, 2021, 5, 1760-1769.	5.2	22
23	Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite. Cancers, 2021, 13, 1756.	3.7	8
24	Impact of <scp><i>PPM1D</i></scp> mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. American Journal of Hematology, 2021, 96, E207-E210.	4.1	2
25	Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Advances, 2021, 5, 2294-2304.	5.2	60
26	Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. Haematologica, 2021, 106, 2986-2989.	3.5	5
27	Induced dendritic cells co-expressing GM-CSF/IFN-α/tWT1 priming T and B cells and automated manufacturing to boost GvL. Molecular Therapy - Methods and Clinical Development, 2021, 21, 621-641.	4.1	5
28	Treatment for Relapsed/Refractory Acute Myeloid Leukemia. HemaSphere, 2021, 5, e572.	2.7	26
29	Evidence for a lowâ€penetrant extended phenotype of rhabdoid tumor predisposition syndrome type 1 from a kindred with gain of <i>SMARCB1</i> exon 6. Pediatric Blood and Cancer, 2021, 68, e29185.	1.5	0
30	Clonal evolution of acute myeloid leukemia with <i>FLT3</i> -ITD mutation under treatment with midostaurin. Blood, 2021, 137, 3093-3104.	1.4	91
31	Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123. Viruses, 2021, 13, 1365.	3.3	16
32	A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 1-12.	1.3	9
33	Rationalization of the Activity Profile of Pyruvate Kinase Isozyme M2 (PKM2) Inhibitors using 3D QSAR. Current Topics in Medicinal Chemistry, 2021, 21, 2258-2271.	2.1	3
34	Measurable Residual Disease in AML. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S116-S118.	0.4	0
35	Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI. Blood Advances, 2021, 5, 4485-4499.	5.2	10
36	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 164.	6.2	29

#	Article	lF	CITATIONS
37	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2021, 138, 2753-2767.	1.4	305
38	Allogeneic, CD34 +, Umbilical Cordblood-Derived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease. Blood, 2021, 138, 1745-1745.	1.4	2
39	EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia. Blood, 2021, 138, 610-610.	1.4	2
40	Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications. Blood, 2021, 138, 692-692.	1.4	1
41	Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation. Blood, 2021, 138, 611-611.	1.4	0
42	Mouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia. Cancers, 2021, 13, 6192.	3.7	4
43	In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. Leukemia, 2020, 34, 416-426.	7.2	13
44	Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia. Haematologica, 2020, 105, 1294-1305.	3.5	8
45	FLAâ€IDA salvage chemotherapy combined with a sevenâ€day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia. British Journal of Haematology, 2020, 188, e11-e15.	2.5	27
46	Gemtuzumab Ozogamicin in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. Journal of Clinical Oncology, 2020, 38, 623-632.	1.6	73
47	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. Journal of Clinical Oncology, 2020, 38, 257-270.	1.6	63
48	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Advances, 2020, 4, 4945-4954.	5.2	34
49	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. Journal of Hematology and Oncology, 2020, 13, 92.	17.0	28
50	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia, 2020, 34, 2903-2913.	7.2	38
51	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372
52	Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leukemia and Lymphoma, 2020, 61, 3287-3305.	1.3	2
53	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with <i>NPM1</i> -mutated AML: results from the AMLSG 09-09 trial. Blood, 2020, 136, 3041-3050.	1.4	73
54	Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. Blood Advances, 2020, 4, 6342-6352.	5.2	45

#	Article	IF	CITATIONS
55	<i>SF3B1</i> -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	1.4	195
56	A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. British Journal of Haematology, 2020, 190, e169-e173.	2.5	14
57	Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. Leukemia, 2020, 34, 2951-2963.	7.2	13
58	Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia. Annals of Hematology, 2020, 99, 1415-1417.	1.8	2
59	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood, 2020, 135, 371-380.	1.4	127
60	lvosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant <i>IDH1</i> AML: Results from Matched Comparisons to Historical Controls. Blood, 2020, 136, 18-19.	1.4	3
61	CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Blood, 2020, 136, 387-400.	1.4	46
62	Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia. Cancers, 2020, 12, 2766.	3.7	29
63	The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408). Blood, 2020, 136, 14-14.	1.4	3
64	<i>IDH</i> Mutations Are Associated with an Increased Risk of Coronary Artery Disease and Cardiotoxicity in Patients with Established AML. Blood, 2020, 136, 32-33.	1.4	0
65	Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial. Blood, 2020, 136, 9-10.	1.4	1
66	Mutational Landscape of Relapsed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML). Blood, 2020, 136, 42-42.	1.4	0
67	Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia. Blood, 2020, 136, 17-18.	1.4	3
68	First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease. Blood, 2020, 136, 8-9.	1.4	4
69	ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF. Leukemia, 2019, 33, 99-109.	7.2	19
70	Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation. Cancer Immunology, Immunotherapy, 2019, 68, 1891-1899.	4.2	10
71	Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation. European Journal of Haematology, 2019, 103, 552-557.	2.2	12
72	Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood, 2019, 134, 1608-1618.	1.4	85

#	Article	IF	CITATIONS
73	Message from the void: MRD analysis from ctDNA. Blood, 2019, 133, 2631-2633.	1.4	1
74	Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo. Annals of Hematology, 2019, 98, 1905-1918.	1.8	61
75	How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 411-420.	3.8	16
76	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nature Communications, 2019, 10, 2031.	12.8	87
77	Emerging strategies to target the dysfunctional cohesin complex in cancer. Expert Opinion on Therapeutic Targets, 2019, 23, 525-537.	3.4	12
78	Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2019, 37, 375-385.	1.6	163
79	Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer–Based "Off-the-Shelf―Acute Myeloid Leukemia Immunotherapies. Human Gene Therapy, 2019, 30, 381-401.	2.7	36
80	Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood, 2019, 133, 2233-2242.	1.4	121
81	The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia. Cancers, 2019, 11, 1663.	3.7	10
82	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia, 2019, 33, 379-389.	7.2	396
83	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood, 2019, 133, 840-851.	1.4	228
84	Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. Leukemia, 2019, 33, 1313-1323.	7.2	20
85	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood, 2019, 133, 1140-1151.	1.4	96
86	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. Leukemia, 2019, 33, 1124-1134.	7.2	29
87	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	7.2	195
88	Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial Journal of Clinical Oncology, 2019, 37, 7010-7010.	1.6	4
89	First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study Journal of Clinical Oncology, 2019, 37, 7043-7043.	1.6	6
90	Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG). Blood, 2019, 134, 2740-2740.	1.4	0

#	Article	IF	CITATIONS
91	Efficacy of Chemotherapy, Phd-Inhibitor Molidustat or BRD4 Inhibitor JQ1 in Combination with Targeted Inhibition of Mutated IDH1 in Human AML In Vivo. Blood, 2019, 134, 3933-3933.	1.4	0
92	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2018, 131, 1275-1291.	1.4	796
93	Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndrome. Haematologica, 2018, 103, 614-625.	3.5	21
94	DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia, 2018, 32, 30-37.	7.2	50
95	RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo. Leukemia, 2018, 32, 224-226.	7.2	15
96	Chromothripsis is linked to <i>TP53</i> alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype. Haematologica, 2018, 103, e17-e20.	3.5	53
97	Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia. Haematologica, 2018, 103, 246-255.	3.5	7
98	Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer. Expert Opinion on Therapeutic Targets, 2018, 22, 107-121.	3.4	22
99	Epigenetics in myelodysplastic syndromes. Seminars in Cancer Biology, 2018, 51, 170-179.	9.6	45
100	Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2018, 36, 1007-1016.	1.6	67
101	Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion. International Journal of Molecular Sciences, 2018, 19, 3269.	4.1	8
102	Phase I/ <scp>II</scp> study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (<scp>AMLSG</scp> 17â€10 <scp>CIARA</scp> trial). British Journal of Haematology, 2018, 183, 235-241.	2.5	2
103	Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood, 2018, 132, 1703-1713.	1.4	237
104	Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene, 2018, 37, 5269-5280.	5.9	65
105	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial. Leukemia, 2018, 32, 1621-1630.	7.2	81
106	Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study. Blood, 2018, 132, 81-81.	1.4	5
107	Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group. Blood, 2018, 132, 1501-1501.	1.4	3
108	Analysis of anti-leukemic activity, predictive biomarker candidates, immune activation and pharmakodynamics in R/R AML and MDS in response to treatment with bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a phase II open-label, multi-centre study Journal of Clinical Oncology, 2018, 36, 7020-7020.	1.6	1

#	Article	IF	CITATIONS
109	The immunomodulatory activity of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome Journal of Clinical Oncology, 2018, 36, 70-70.	1.6	1
110	T Regulatory Cell Receptor Repertoire Focusing and Clonal Expansion Indicates Control of Acute GvHD after Donor Lymphocyte Infusion. Blood, 2018, 132, 822-822.	1.4	0
111	Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. Leukemia, 2017, 31, 1217-1220.	7.2	49
112	Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. Leukemia, 2017, 31, 2020-2028.	7.2	97
113	Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia, 2017, 31, 1306-1313.	7.2	78
114	Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nature Genetics, 2017, 49, 332-340.	21.4	229
115	Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group. Leukemia, 2017, 31, 1012-1015.	7.2	14
116	Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. Molecular Therapy, 2017, 25, 165-180.	8.2	149
117	Human Î ³ δT cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. Nature Immunology, 2017, 18, 393-401.	14.5	208
118	Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization. Haematologica, 2017, 102, e170-e174.	3.5	13
119	Therapy-related myeloid neoplasms. Current Opinion in Hematology, 2017, 24, 152-158.	2.5	30
120	Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. Annals of Hematology, 2017, 96, 1361-1372.	1.8	49
121	An optimized lentiviral vector system for conditional RNAi and efficient cloning of microRNA embedded short hairpin RNA libraries. Biomaterials, 2017, 139, 102-115.	11.4	24
122	Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1095-1101.	2.0	89
123	The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia. Annals of Hematology, 2017, 96, 895-904.	1.8	7
124	Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Annals of Hematology, 2017, 96, 1993-2003.	1.8	108
125	The actin binding protein plastin-3 is involved in the pathogenesis of acute myeloid leukemia. Experimental Hematology, 2017, 53, S58.	0.4	0
126	Clinical impact of <scp>KMT</scp> 2C and <scp>SPRY</scp> 4 expression levels in intensively treated younger adult acute myeloid leukemia patients. European Journal of Haematology, 2017, 99, 544-552.	2.2	5

#	Article	IF	CITATIONS
127	Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. Leukemia, 2017, 31, 1286-1295.	7.2	44
128	Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset. Frontiers in Immunology, 2017, 8, 1100.	4.8	7
129	Axl blockade in vitro and in patients with high-risk MDS by the small molecule inhibitor BGB324 Journal of Clinical Oncology, 2017, 35, 7059-7059.	1.6	2
130	VH1 Family Immunoglobulin Repertoire Sequencing after Allogeneic Hematopoietic Stem Cell Transplantation. PLoS ONE, 2017, 12, e0168096.	2.5	7
131	miR-625-3p is upregulated in CD8+ T cells during early immune reconstitution after allogeneic stem cell transplantation. PLoS ONE, 2017, 12, e0183828.	2.5	10
132	Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy. Oncotarget, 2017, 8, 73871-73883.	1.8	10
133	Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening. Current Cancer Drug Targets, 2016, 16, 818-828.	1.6	17
134	Clonal Hematopoiesis of Indeterminate Potential. Deutsches Ärzteblatt International, 2016, 113, 317-22.	0.9	65
135	MP475OXALIPLATIN PHARMACOKINETICS ON HEMODIALYSIS IN A PATIENT WITH DIFFUSE LARGE B-CELL LYMPHOMA. Nephrology Dialysis Transplantation, 2016, 31, i499-i499.	0.7	0
136	RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. Cancer Cell, 2016, 30, 75-91.	16.8	144
137	Letter to the Editor: Production of Mature Healthy Hematopoietic Cells from Induced Pluripotent Stem Cells Derived from an AML Diagnostic Sample Containing the t(8;21) Translocation. Stem Cells, 2016, 34, 797-799.	3.2	6
138	Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group. Leukemia, 2016, 30, 2248-2250.	7.2	36
139	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. Hematology American Society of Hematology Education Program, 2016, 2016, 24-32.	2.5	32
140	Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia, 2016, 30, 1672-1681.	7.2	99
141	Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. Leukemia, 2016, 30, 1708-1715.	7.2	38
142	RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia, 2016, 30, 2160-2168.	7.2	197
143	Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform. Molecular Therapy, 2016, 24, 1216-1226.	8.2	20
144	Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML. Experimental Hematology, 2016, 44, 713-726.e14.	0.4	16

1

#	Article	IF	CITATIONS
145	Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators. Rna, 2016, 22, 1535-1549.	3.5	40
146	MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development. Experimental Hematology, 2016, 44, 1166-1171.	0.4	18
147	Genomic Classification and Prognosis in Acute Myeloid Leukemia. New England Journal of Medicine, 2016, 374, 2209-2221.	27.0	3,067
148	Oxaliplatin pharmacokinetics on hemodialysis in a patient with diffuse large B cell lymphoma. Annals of Hematology, 2016, 95, 649-650.	1.8	3
149	miR-21 promotes fibrosis in an acute cardiac allograft transplantation model. Cardiovascular Research, 2016, 110, 215-226.	3.8	61
150	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. Hematology American Society of Hematology Education Program, 2016, 2016, 24-32.	2.5	34
151	Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG). Blood, 2016, 128, 1207-1207.	1.4	10
152	Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial. Blood, 2016, 128, 449-449.	1.4	18
153	TCR Diversity Is a Predictive Marker for Donor Lymphocyte Infusion Response. Blood, 2016, 128, 4605-4605.	1.4	2
154	Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. Blood, 2016, 128, 589-589.	1.4	11
155	Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo. Blood, 2016, 128, 745-745.	1.4	7
156	A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. Blood, 2016, 128, 99-99.	1.4	36
157	A first-in-patient phase I study of BGB324, a selective Axl kinase inhibitor in patients with refractory/relapsed AML and high-risk MDS Journal of Clinical Oncology, 2016, 34, 2561-2561.	1.6	12
158	A phase 2 study of azacitidine (5-AZA) with or without birinapant in subjects with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) Journal of Clinical Oncology, 2016, 34, 7060-7060.	1.6	7
159	Clinical Impact of KMT2C and SPRY4 Expression Levels in Intensively Treated Younger Adult Acute Myeloid Leukemia Patients. Blood, 2016, 128, 1663-1663.	1.4	0
160	Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10) Tj ETQq0 0 ()rgg∄T/Ov	er lo ck 10 Tf :
161	Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia. Blood, 2016, 128, 3995-3995.	1.4	1

¹⁶²The miRNA-193 Family Is a Potent Tumor-Suppressor and a Biomarker for Poor Prognosis in Acute
Myeloid Leukemia. Blood, 2016, 128, 1534-1534.1.4

#	Article	IF	CITATIONS
163	Genetic Profile of Acute Erythroid Leukemia. Blood, 2016, 128, 40-40.	1.4	1
164	HSC Hierarchy in Primary Myelofibrosis. Blood, 2016, 128, 4285-4285.	1.4	0
165	Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. Haematologica, 2015, 100, e122-e124.	3.5	20
166	ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica, 2015, 100, 324-330.	3.5	86
167	Expression of Hedgehog Pathway Mediator <i>GLI</i> Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects. Clinical Cancer Research, 2015, 21, 2388-2398.	7.0	88
168	Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. Haematologica,	3.5	50
169	2015, 100, 400-408. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncology, The, 2015, 16, 1025-1036.	10.7	129
170	MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Experimental Hematology, 2015, 43, 858-868.e7.	0.4	28
171	Enigmas of IDH mutations in hematology/oncology. Experimental Hematology, 2015, 43, 685-697.	0.4	22
172	How I treat refractory and early relapsed acute myeloid leukemia. Blood, 2015, 126, 319-327.	1.4	245
173	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating <i>FLT3</i> mutations. British Journal of Haematology, 2015, 169, 694-700.	2.5	90
174	Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. Leukemia, 2015, 29, 1942-1945.	7.2	18
175	Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling. Leukemia, 2015, 29, 157-168.	7.2	25
176	Effective Treatment of Human CML By RNAi In Vivo in a Xenotransplantation Mouse Model. Blood, 2015, 126, 1261-1261.	1.4	2
177	Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG). Blood, 2015, 126, 226-226.	1.4	4
178	Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2586-2586.	1.4	1
179	Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606). Blood, 2015, 126, 322-322.	1.4	32
180	Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation. Blood, 2015, 126, 352-352.	1.4	2

#	Article	IF	CITATIONS
181	Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia. Blood, 2015, 126, 3744-3744.	1.4	7
182	Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study. Blood, 2015, 126, 3789-3789.	1.4	3
183	Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG). Blood, 2015, 126, 3818-3818.	1.4	1
184	Dissecting Genetic and Phenotypic Heterogeneity to Map Molecular Phylogenies and Deliver Personalized Outcome and Treatment Predictions in AML. Blood, 2015, 126, 803-803.	1.4	2
185	Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data. Blood, 2015, 126, 85-85.	1.4	1
186	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	1.4	85
187	Molecular Predictors of Outcome in Patients with MDS and AML Following MDS after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 912-912.	1.4	5
188	Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis. Blood, 2015, 126, 224-224.	1.4	0
189	The Role of microRNA-155 in Mouse Models of MLL -AML. Blood, 2015, 126, 2446-2446.	1.4	Ο
190	The Mir-193 Family Antagonizes Stem Cell Pathways and Is a Potent Tumor Suppressor in Childhood and Adult Acute Myeloid Leukemia. Blood, 2015, 126, 1244-1244.	1.4	0
191	A Tumor Suppressor microRNA Defines the Leukemic Hierarchy in Acute Myeloid Leukemia. Blood, 2015, 126, 3653-3653.	1.4	Ο
192	Patient Derived Xenotransplantation Model of Atypical Chronic Myeloid Leukemia (aCML). Blood, 2015, 126, 2836-2836.	1.4	0
193	Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype. BMC Genomics, 2014, 15, 784.	2.8	25
194	Genetic Deletion of SEPT7 Reveals a Cell Type-Specific Role of Septins in Microtubule Destabilization for the Completion of Cytokinesis. PLoS Genetics, 2014, 10, e1004558.	3.5	90
195	<i>TET2</i> mutations in cytogenetically normal acute myeloid leukemia: Clinical implications and evolutionary patterns. Genes Chromosomes and Cancer, 2014, 53, 824-832.	2.8	27
196	All-in-One inducible lentiviral vector systems based on drug controlled FLP recombinase. Biomaterials, 2014, 35, 4345-4356.	11.4	21
197	Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. Annals of Hematology, 2014, 93, 193-202.	1.8	7
198	Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Leukemia, 2014, 28, 1552-1555.	7.2	56

#	Article	IF	CITATIONS
199	Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood, 2014, 123, 914-920.	1.4	167
200	Low frequency of calreticulin mutations in MDS patients. Leukemia, 2014, 28, 1933-1934.	7.2	6
201	Gfi1 as a new target and predictive marker in AML. Experimental Hematology, 2014, 42, S20.	0.4	0
202	Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia. Annals of Hematology, 2014, 93, 977-982.	1.8	6
203	Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. Haematologica, 2014, 99, 1456-1464.	3.5	26
204	Genetic characterization of acquired aplastic anemia by targeted sequencing. Haematologica, 2014, 99, e165-e167.	3.5	51
205	Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13. Blood, 2014, 124, 3608-3612.	1.4	23
206	Results of the "Evaluation of NGS in AML-Diagnostics (ELAN)―Study – an Inter-Laboratory Comparison Performed in 10 European Laboratories. Blood, 2014, 124, 2374-2374.	1.4	1
207	Prognostic Impact of Splicing Factor Mutations in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 3171-3171.	1.4	1
208	A Novel Inhibitor of Mutant IDH1 Induces Differentiation in Vivo and Prolongs Survival in a Mouse Model of Leukemia. Blood, 2014, 124, 3598-3598.	1.4	8
209	The Metabolite R-2-Hydroxyglutarate (R2HC) Collaborates with HoxA9 to Induce Monocytic Leukemia. Blood, 2014, 124, 366-366.	1.4	1
210	Casein Kinase 1A1 (CSNK1A1) Is Recurrently Mutated in MDS Patients with Deletion of Chromosome 5q. Blood, 2014, 124, 4643-4643.	1.4	1
211	Cell Fate Decisions in Malignant Hematopoiesis: Leukemia Phenotype Is Determined by Distinct Functional Domains of the MN1 Oncogene. PLoS ONE, 2014, 9, e112671.	2.5	15
212	Dose Dependent Role of Gfi1 in Human MDS and AML and Its Suitability As a Novel Target. Blood, 2014, 124, 777-777.	1.4	0
213	EZH2 Mutations Are Drivers of Clonal Hematopoiesis and Leukemic Transformation in a Mouse Model of Primary Myelofibrosis. Blood, 2014, 124, 3211-3211.	1.4	1
214	Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). Blood, 2014, 124, 1254-1254.	1.4	0
215	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT, Blood, 2014, 124, 324-324.	1.4	2
216	Hoxa9/Meis1 Mediate Leukemic Programming through Microrna-155. Blood, 2014, 124, 884-884.	1.4	0

#	Article	IF	CITATIONS
217	In Vivo Methylome Changes in Purified Peripheral Blood Blasts and T Cells of AML Patients Treated with Decitabine: Statistical Modelling of a Hypomethylation Response. Blood, 2014, 124, 870-870.	1.4	0
218	High-Throughput Drug Screening Identifies Pyrimethamine As a Potent and Selective Inhibitor of Acute Myeloid Leukemia. Blood, 2014, 124, 2304-2304.	1.4	0
219	Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia. Annals of Hematology, 2013, 92, 1079-1090.	1.8	33
220	Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. Annals of Hematology, 2013, 92, 315-323.	1.8	48
221	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood, 2013, 121, 4769-4777.	1.4	162
222	Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood, 2013, 122, 2443-2452.	1.4	178
223	MN1 regulates self-renewal and differentiation through distinct domains. Experimental Hematology, 2013, 41, S52-S53.	0.4	0
224	Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. Annals of Hematology, 2013, 92, 747-758.	1.8	61
225	SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia, 2013, 27, 2072-2075.	7.2	60
226	Analysis of NUP98/NSD1 translocations in adult AML and MDS patients. Leukemia, 2013, 27, 750-754.	7.2	42
227	Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood, 2013, 122, 2877-2887.	1.4	186
228	Myelodysplastic syndromes are induced by histone methylationââ,¬â€œaltering ASXL1 mutations. Journal of Clinical Investigation, 2013, 123, 4627-4640.	8.2	140
229	Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The	1.4	3
230	Expression Of Hedgehog Pathway Mediator Gli2 Represents a Clinically Negative Prognostic Marker In Acute Myeloid Leukemia and Its Inhibitor GANT61 Exerts Anti-Leukemic Effects In Vitro. Blood, 2013, 122, 53-53.	1.4	3
231	Gfi1 As a Novel Prognostic Marker and Tumor Suppressor In Acute Myeloid Leukemia. Blood, 2013, 122, 2516-2516.	1.4	0
232	Analysis Of Micro-RNA-142 Mutations In a Cohort Of 944 Patients With MDS and AML. Blood, 2013, 122, 2804-2804.	1.4	0
233	Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome. Blood, 2013, 122, 2555-2555.	1.4	0
234	Clinical Impact of GATA2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSG). Blood, 2013, 122, 1332-1332.	1.4	0

#	Article	IF	CITATIONS
235	The Clinical and Prognostic Influence Of Mutations In The Cohesin Complex In Acute Myeloid Leukemia. Blood, 2013, 122, 1314-1314.	1.4	о
236	Prognostic Value Of Five-Group Cytogenetic Risk Classification In Patients With MDS After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study Of The Chronic Malignancies Working Party Of The EBMT. Blood, 2013, 122, 2092-2092.	1.4	0
237	C-Terminal-Truncating ASXL1 Mutations Induce MDS Via Inhibition Of PRC2. Blood, 2013, 122, 471-471.	1.4	Ο
238	SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia, 2012, 26, 1137-1140.	7.2	83
239	Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia. Leukemia, 2012, 26, 289-295.	7.2	36
240	Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood, 2012, 119, e96-e99.	1.4	65
241	Update on cytogenetic and molecular changes in myelodysplastic syndromes. Leukemia and Lymphoma, 2012, 53, 525-536.	1.3	21
242	Functional role of BAALC in leukemogenesis. Leukemia, 2012, 26, 532-536.	7.2	33
243	Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood, 2012, 119, 3578-3584.	1.4	391
244	Prognostic significance of combined MN1, ERC, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. Annals of Hematology, 2012, 91, 1221-1233.	1.8	37
245	Nextâ€generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with <i>FLT3</i> â€ITD or <i>NPM1</i> mutations. Genes Chromosomes and Cancer, 2012, 51, 689-695.	2.8	114
246	<i><scp>ID</scp>1</i> expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia. British Journal of Haematology, 2012, 158, 208-215.	2.5	9
247	Clinical Impact of TERT A1062T Mutations in Younger Patients with Acute Myeloblastic Leukemia. Blood, 2012, 120, 1381-1381.	1.4	2
248	Prognostic Effect of Mutations in the Splicing Gene Machinery in 339 Patients with MDS or Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 357-357.	1.4	3
249	Impact of ASXL1 Mutations On Outcome After Reduced Intensity Allograft in Patients with Myelofibrosis. Blood, 2012, 120, 1740-1740.	1.4	0
250	Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis. Blood, 2012, 120, 770-770.	1.4	0
251	Frequency and Prognostic Impact of NUP98/NSD1 Translocations in Adult AML and MDS Patients. Blood, 2012, 120, 1402-1402.	1.4	2
252	Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood, 2011, 118, 3350-3358.	1.4	90

#	Article	IF	CITATIONS
253	Incidence and Prognostic Influence of <i>DNMT3A</i> Mutations in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 2889-2896.	1.6	351
254	Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica, 2011, 96, 1870-1873.	3.5	67
255	Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood, 2011, 117, 4561-4568.	1.4	99
256	DNMT3A mutations are rare in childhood acute myeloid leukemia. Haematologica, 2011, 96, 1238-1240.	3.5	34
257	FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. Haematologica, 2011, 96, 681-686.	3.5	45
258	Cell of Origin in AML: Susceptibility to MN1-Induced Transformation Is Regulated by the MEIS1/AbdB-like HOX Protein Complex. Cancer Cell, 2011, 20, 39-52.	16.8	76
259	Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. Annals of Hematology, 2011, 90, 273-281.	1.8	14
260	Genetic changes of miR-182 G106A: rather a polymorphism than a somatic mutation. Annals of Hematology, 2011, 90, 1107-1109.	1.8	1
261	Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. Annals of Hematology, 2011, 90, 1047-1058.	1.8	36
262	Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML–BFM and DCOG study groups. Leukemia, 2011, 25, 1704-1710.	7.2	73
263	Prognostic Importance of Histone Methyltransferase <i>MLL5</i> Expression in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 682-689.	1.6	53
264	Prognostic Significance of <i>ASXL1</i> Mutations in Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2011, 29, 2499-2506.	1.6	258
265	Reply to S. Masuda. Journal of Clinical Oncology, 2011, 29, 4593-4594.	1.6	2
266	All-Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia – Results of the AMLSG 07-04 Randomized Treatment Trial. Blood, 2011, 118, 80-80.	1.4	18
267	ID1 Expression Correlates with CEBPA Mutational Status and Is Not An Independent Risk Factor in Cytogenetically Normal AML,. Blood, 2011, 118, 3554-3554.	1.4	0
268	Mutations of the Spliceosome Complex Genes Occur In Adult Patients but Are Very Rare In Children with Myeloid Neoplasia. Blood, 2011, 118, 2797-2797.	1.4	0
269	Next Generation Sequencing for Minimal Residual Disease Monitoring in AML Patients with FLT3-ITD,. Blood, 2011, 118, 3548-3548.	1.4	0
270	IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica, 2010, 95, 1668-1674.	3.5	177

#	Article	IF	CITATIONS
271	Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood, 2010, 116, 614-616.	1.4	170
272	Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3. Blood, 2010, 115, 4071-4082.	1.4	28
273	Extrinsic signals determine myeloid-erythroid lineage switch in MN1 leukemia. Experimental Hematology, 2010, 38, 174-179.	0.4	5
274	An open-label, Phase I study of cediranib (RECENTINâ,,¢) in patients with acute myeloid leukemia. Leukemia Research, 2010, 34, 196-202.	0.8	40
275	Reply to I.H.I.M. Hollink et al. Journal of Clinical Oncology, 2010, 28, e527-e528.	1.6	4
276	Phosphoinositide Phospholipase Cβ1 (<i>PI-PLC</i> β <i>1</i>) Gene in Myelodysplastic Syndromes and Cytogenetically Normal Acute Myeloid Leukemia: Not a Deletion, but Increased <i>PI-PLC</i> β <i>1</i> Expression Is an Independent Prognostic Factor. Journal of Clinical Oncology, 2010, 28, e384-e387.	1.6	5
277	Single Nucleotide Polymorphism in the Mutational Hotspot of <i>WT1</i> Predicts a Favorable Outcome in Patients With Cytogenetically Normal Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 578-585.	1.6	119
278	Biologic and experimental variation of measured cancer stem cells. Cell Cycle, 2010, 9, 909-912.	2.6	5
279	Impact of <i>IDH1</i> R132 Mutations and an <i>IDH1</i> Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor. Journal of Clinical Oncology, 2010, 28, 2356-2364.	1.6	229
280	The Hematopoietic Growth Factors in Acute Leukemia: A European Perspective. Cancer Treatment and Research, 2010, 157, 339-362.	0.5	4
281	MN1 Inhibits Myeloid Differentiation by Transcriptional Repression of EGR2. Blood, 2010, 116, 229-229.	1.4	1
282	Mir-223 Is Dispensable for the Onset of Acute Myeloid Leukemia. Blood, 2010, 116, 501-501.	1.4	2
283	Functional Role of BAALC In Leukemogenesis. Blood, 2010, 116, 4194-4194.	1.4	0
284	FLT3-ITD and Age Are the Major Prognostic Factors In Relapsed AML with Normal Karyotype. Blood, 2010, 116, 1719-1719.	1.4	1
285	Competition In Engraftment of Normal Hematopoietic Stem Cells and Leukemic Stem Cells. Blood, 2010, 116, 4836-4836.	1.4	0
286	High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood, 2009, 113, 2028-2037.	1.4	51
287	Loss of Mll5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation. Blood, 2009, 113, 1432-1443.	1.4	101
288	Priming reloaded?. Blood, 2009, 114, 925-926.	1.4	3

#	Article	IF	CITATIONS
289	Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Blood, 2009, 114, 3983-3993.	1.4	69
290	A Potent Stimulator of Self-Renewal in Combination with MEIS1 Overexpression Allows the Transformation of Late Committed Myeloid Progenitors Blood, 2009, 114, 1434-1434.	1.4	0
291	Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3. Experimental Hematology, 2008, 36, 845-859.	0.4	56
292	In-depth characterization of the microRNA transcriptome in a leukemia progression model. Genome Research, 2008, 18, 1787-1797.	5.5	162
293	Comprehensive Profiling of Micrornas in Murine Hematopoietic Stem Cells and Lineages Using a Microfluidics Approach. Blood, 2008, 112, 2468-2468.	1.4	1
294	Use of Colony-Stimulating Factors for Chemotherapy-Associated Neutropenia: Review of Current Guidelines. Seminars in Hematology, 2007, 44, 148-156.	3.4	32
295	MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood, 2007, 110, 1639-1647.	1.4	133
296	An Open, Phase I Study of Cediranib in Patients with Acute Myeloid Leukemia (AML) Blood, 2007, 110, 895-895.	1.4	0
297	Neurotrophin Receptors and Ligands Are Highly Expressed in Acute Leukemia and Promote Leukemogenesis Blood, 2007, 110, 696-696.	1.4	0
298	High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood, 2006, 108, 3898-3905.	1.4	217
299	Recombinant human erythropoietin in the treatment of nonrenal anemia. Annals of Hematology, 2006, 85, 69-78.	1.8	19
300	Colony-stimulating factors in the management of neutropenia and its complications. Annals of Hematology, 2005, 84, 697-708.	1.8	30
301	Cytotoxicity determination without photochemical artifacts. Cancer Letters, 2005, 223, 57-66.	7.2	10
302	MN1 Expression Predicts Prognosis of Acute Myeloid Leukemia with Normal Cytogenetics Blood, 2005, 106, 2351-2351.	1.4	0
303	Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. Haematologica, 2005, 90, 1484-92.	3.5	67
304	Drug-Response Signature Predicts Outcome in Adult Acute Myeloid Leukemia and Associates Poor Response with Molecular Characteristics of Hematopoietic Stem Cells Blood, 2004, 104, 2024-2024.	1.4	0
305	Clonal Evolution at First Sight: A Combined Visualization of Diverse Diagnostic Methods Improves Understanding of Leukemic Progression. Frontiers in Oncology, 0, 12, .	2.8	2